Press releases

Xspray Pharma has carried out a directed share issue raising gross proceeds of approximately SEK 92 million

Xspray Pharma contemplates a directed share issue to continue development of its product portfolio

Additional product patent in the United States for HyNap-Dasa

Resolution on long-term incentive programme at extraordinary general meeting in Xspray Pharma on 28 November 2018

Xspray Pharma prepares for listing on main list

Notice of extraordinary general meeting in Xspray Pharma AB (publ)

Xspray Pharma’s HyNap-Dasa Shows Formal Bioequivalence

Ribbskottet AB increases its stake in Xspray Pharma

Xspray Pharma announces positive clinical data for its lead product candidate HyNap-Dasa

Xspray Pharma publishing Interim Report Q2, January-June 2018

Notice of annual general meeting in Xspray Pharma AB (publ)

Bulletin from the extraordinary general meeting of Xspray Pharma AB (publ)

Notice of extraordinary general meeting in Xspray Pharma AB (publ)

Xspray Pharma proposes a directed issue of 1,350,000 shares corresponding to approximately SEK 88 million to expand the product portfolio

Xspray Pharma achieves positive clinical results for the ANDA-drug candidate HyNap-Dasa

Xspray Pharma receives the first product patent in the United States for HyNap-Dasa

Xspray Pharma announces positive clinical data for its HyNap-dasatinib product candidate, HyNap-Dasa

Xspray Pharma receives its first product patents in Japan